trending Market Intelligence /marketintelligence/en/news-insights/trending/lv1sc4bbgcvjpflgt37svq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

European regulator maintains rejection of PharmaMar blood cancer drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


European regulator maintains rejection of PharmaMar blood cancer drug

The European Medicines Agency maintained its negative opinion on Pharma Mar SA's blood cancer drug Aplidin.

In December 2017, the agency's Committee for Medicinal Products for Human Use rejected Pharma Mar's application to market the drug, also known as plitidepsin, as a treatment for multiple myeloma. The company requested that the committee revisit its decision in January.

Madrid-based Pharma Mar develops anti-cancer drugs derived from marine organisms.

Multiple myeloma is a type of blood cancer that occurs in the white blood cells and accumulates in the bone marrow.